Benefits of Indole-3-Carbinol (I3C)

Evidence-Based Benefits

• Estrogen metabolism — I3C at 300-400mg daily has been shown to significantly increase the urinary 2:16α-OHE1 ratio, indicating enhanced 2-hydroxylation of estrogen; this shift is associated with potentially reduced proliferative signaling
• Recurrent respiratory papillomatosis — Rosen et al. (1998) found that I3C at 200mg daily stopped or reduced papilloma growth in 33% of patients with HPV-related RRP, one of the few clinical applications with direct evidence
• CYP1A1 induction — I3C and its metabolites are potent inducers of CYP1A1, a Phase I detoxification enzyme involved in estrogen 2-hydroxylation and xenobiotic metabolism
• Cervical health — Bell et al. (2000) studied I3C for cervical intraepithelial neoplasia (CIN) and found regression in 50% of patients taking 200mg daily, compared to none in the placebo group

What the Research Says

I3C research spans estrogen metabolism, HPV-related conditions, and cancer prevention. Rosen et al. (1998) published a key study on recurrent respiratory papillomatosis showing that 200mg of I3C daily stopped papilloma growth in a third of patients. Bell et al. (2000) studied 30 women with CIN II-III and found that 200mg of I3C daily led to CIN regression in 50% of participants over 12 weeks. For estrogen metabolism, multiple studies confirm that I3C shifts the 2:16α-OHE1 ratio, though the effect is more variable than with DIM due to pH-dependent conversion kinetics. The 2017 consensus in the field has generally shifted to recommending DIM over I3C for estrogen modulation, as DIM bypasses the variable stomach conversion and provides a more consistent dose of the primary active metabolite.

Related Conditions